Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.74)
# 3,383
Out of 5,122 analysts
60
Total ratings
44.19%
Success rate
-2.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $24 → $33 | $21.65 | +52.42% | 7 | Dec 15, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $141 → $157 | $107.97 | +45.41% | 11 | Dec 12, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Neutral | $27 → $30 | $33.28 | -9.86% | 6 | Oct 21, 2025 | |
| GERN Geron | Reinstates: Sell | $1 | $1.47 | -31.97% | 4 | Jul 10, 2025 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $29.11 | -24.41% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $9.90 | +51.52% | 2 | May 14, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $5.13 | +153.41% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $37.32 | -24.97% | 7 | Jan 9, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $1.49 | +4,195.30% | 6 | Aug 15, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $216 → $184 | $57.78 | +218.45% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $3.54 | +493.22% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $36.06 | -61.18% | 2 | Dec 20, 2022 |
Roivant Sciences
Dec 15, 2025
Maintains: Buy
Price Target: $24 → $33
Current: $21.65
Upside: +52.42%
Rhythm Pharmaceuticals
Dec 12, 2025
Maintains: Buy
Price Target: $141 → $157
Current: $107.97
Upside: +45.41%
IDEAYA Biosciences
Oct 21, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $33.28
Upside: -9.86%
Geron
Jul 10, 2025
Reinstates: Sell
Price Target: $1
Current: $1.47
Upside: -31.97%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $29.11
Upside: -24.41%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $9.90
Upside: +51.52%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $5.13
Upside: +153.41%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $37.32
Upside: -24.97%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $1.49
Upside: +4,195.30%
RAPT Therapeutics
Mar 15, 2023
Maintains: Buy
Price Target: $216 → $184
Current: $57.78
Upside: +218.45%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $3.54
Upside: +493.22%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $36.06
Upside: -61.18%